blue cross blue shield cover glp-1 Why we are changing coverage of drugs for weight loss Blue Cross Blue Shield of

There isnt strong proof that GLP-1 medicines directly cause DME, but its something doctors keep an eye on

Together, these findings suggested high public interest in GLP-1 RA and identified potential priorities for the clinical and policy communities, including monitoring side effects, addressing access barriers, and acknowledging both the physical and psychological benefits of GLP-1 RAs

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A

Rather than overriding the bodys natural systems, it supports themhelping stimulate GLP-1 production, improve insulin sensitivity, and regulate blood sugar in response to food

Mechanism of action All non-insulin, injectable diabetes medications work by Slowing gastric emptying/decreasing gastric motility Stimulating the release of insulin with glucose Suppressing glucagon release after a meal Suppressing appetite/increasing satiety Client education points General teachings Do not inject into the same site as insulin

Ozempic and Mounjaro saw A1c reductions of around 1.5 to 2 percentage points in trials